Drug Patent Monopoly During Covid-19 Outbreaks: How the Government Regulates this?

Devica Rully Masrur; Ogah Chinyere Constance

doi:10.15294/jpcl.v7i1.44391

Drug Patent Monopoly During Covid-19 Outbreaks: How the Government Regulates this?

Devica Rully Masrur⁽¹⁾, Ogah Chinyere Constance⁽²⁾,

DOI: https://doi.org/10.15294/jpcl.v7i1.44391

(1) Faculty of Law, Esa Unggul University
(2) Faculty of Law, Ebonyi State University

Abstract

Health is an inherent human right constitutionally guaranteed, and during the Global Covid-19 Pandemic, the Indonesian government faced a delicate balance between safeguarding public health and complying with its obligations as a member of the WTO under the TRIPS Agreement, which mandates patent protection for medicines, medical devices, and vaccines, crucially needed during the pandemic. International and national laws have addressed these challenges through the TRIPs Protector Article, providing options for member states to take specific measures, such as Parallel Imports, Bolar Provisions, Compulsory Licenses, and Government Use of Patents. These solutions demonstrate that even in emergency situations, the rights of inventors can still be upheld while ensuring access to essential medicines for the public. In the case of Indonesia, the government employed the Government Use of Patents policy through Presidential Regulations Number 77 of 2020, Number 100 of 2021, and Number 101 of 2021, pertaining to Remdesivir and Favipiravir medicines, respectively. This approach, though involving compulsory acquisition, is time-limited, non-exclusive, and provides fair compensation to patent holders, reflecting a balanced and just approach to addressing the critical public health needs during the pandemic.

Keywords

Patents, Drug, Covid-19, Patent Monopoly, Government Regulation

Full Text:

PDF

References

Adakawa, Murtala Ismail, and N. S. Harinarayana. "Insight Into Intellectual Property in Patent Medicine: An Indian Perspective." Unnes Law Journal 8, No. 2 (2022): 377-391. https://doi.org/10.15294/ulj.v8i2.60716

Affandi, Hernadi. "Implementasi Hak atas Kesehatan Menurut Undang-Undang Dasar 1945: antara Pengaturan dan Realisasi Tanggung Jawab Negara." Jurnal Hukum Positum 4, No. 1 (2019): 36-56. https://doi.org/10.35706/positum.v4i1.3006

Agus, Rustam. “Government Use dan Akses Terhadap Obat Covid-19”, Bisnis Indonesia, September 1, 2021. Available online at https://bisnisindonesia.id/article/government-use-dan-akses-terhadap-obat-covid19

Alshrari, Ahmed S. et al. "Innovations and development of COVID-19 vaccines: A patent review." Journal of Infection and Public Health 15, No. 1 (2022): 123-131. https://doi.org/10.1016/j.jiph.2021.10.021

Arimuladi, Setia Untung. "Perlindungan Negara, Paten Vaksin Covid-19, dan Potensi Monopoli." Jurnal Hukum Progresif 9, No. 1 (2021): 50-63. https://doi.org/10.14710/jhp.9.1.50-63

Atmaja, Yustisiana Susila, Budi Santoso, and Irawati Irawati. "Pelindungan Hukum Terhadap Paten Produk Farmasi atas Pelaksanaan Paten oleh Pemerintah (Government Use)." Masalah-Masalah Hukum 50, No. 2 (2021): 196-208. https://doi.org/10.14710/mmh.50.2.2021.196-208

Cahyono, Anang Sugeng. "Implementasi Model Collaborative Governance dalam Penyelesaian Pandemi Covid-19." Publiciana 13, No. 1 (2020): 83-88. https://doi.org/10.36563/publiciana.v13i1.207

Deshko, L. et al. "Patenting of Medicines in Ukraine Through the Prism of the Association Agreement with the EU and the TRIPS Agreement: Improvement in Medical and Administrative Regulations." Georgian Medical News 288 (2019): 154-158.

Devi, Thamidela Mythri, and Bhupathiraju Harika. "Analysis on Generic Medicine v. Patented Medicine." Journal of Positive School Psychology 6, No. 3 (2022): 826-834.

Firdaus, Andi. “Kimia Farma produksi tiga varian obat terapi COVID-19 jenis Azithromycin, Favipiravir dan Remdesivir”, ANTARA News, July 7, 2021. Retrieved from https://sumbar.antaranews.com/berita/443414/kimia-farma-produksi-tiga-varian-obat-terapi-covid-19-jenis-azithromycin-favipiravir-dan-remdesivir

Gabriel, Joseph M. Medical Monopoly: Intellectual Property Rights and the Origins of the Modern Pharmaceutical Industry. (Chicago: University of Chicago Press, 2019).

Hakim, Arief Rahman. “KPPU Temukan Harga Obat Terapi Covid-19 Melambung, Ini Daftarnya” Liputan6 Online, July 30, 2021. Retrieved from https://www.liputan6.com/bisnis/read/4619836/kppu-temukan-harga-obat-terapi-covid-19-melambung-ini-daftarnya

Haugen, Hans Morten. "Does TRIPS (Agreement on Trade‐Related Aspects of Intellectual Property Rights) prevent COVID‐19 vaccines as a global public good?." The Journal of World Intellectual Property 24, No. 3-4 (2021): 195-220. https://doi.org/10.1111/jwip.12187

Hertanti, Rachmi, and Agung Prakoso, “Hentikan Monopoli HAKI Terhadap Covid19, Laksanakan TRIPs Waiver”, Briefing Paper Indonesia for Global Justice, February (2021): 1-17. Online at https://igj.or.id/wp-content/uploads/2021/02/BP-FEB-2021-2.pdf

Hutauruk, Gabriela Madeline, Ahmad M. Ramli, and Tasya Safiranita Ramli. "Pelaksanaan Paten oleh Pemerintah Vaksin dan Obat Covid-19 di Masa Pandemi Berdasarkan Hukum Indonesia dan TRIPs-WTO." Jurnal Sains Sosio Humaniora 6, No. 1 (2022): 538-550. http://dx.doi.org/10.22437/jssh.v6i1.19723

Jaelani, Abdul Kadir, Alexander A. Kurniawan, and Lusia Indrastuti. "Pelaksanaan Standarisasi Pemberian Paten dalam Invensi Bidang Obat-Obatan di Indonesia." Legality: Jurnal Ilmiah Hukum 27, No. 2 (2019): 259-274.

Lindati, Dwiatin, Rohaini Rohaini, and Eka Rusmawati Dianne. "Kepentingan Umum dalam Pemberian Paten Obatdi Indonesia: Menyoal Pemberian Paten Vaksin dan atau Obat Covid-19." Research Report (Lampung: Universitas Lampung, 2021).

Marcowitz-Bitton, Miriam and Yotam Kaplan. "Recalibrating Patent Protection for COVID-19 Vaccines: A Path to Affordable Access and Equitable Distribution." UC Irvine Law Review 12, No. 2 (2022): 423-470.

Mardiansyah, Rico. "Dinamika Politik Hukum Dalam Pemenuhan Hak Atas Kesehatan di Indonesia." Veritas et Justitia 4, No. 1 (2018): 227-251. https://doi.org/10.25123/vej.v4i1.2918

Masnun, Muh Ali, and Dilla Nurfiana Astanti. "Urgensi Pembatasan Hak Eksklusif Paten COVID-19 Melalui Penerapan Lisensi Wajib di Indonesia." Jurnal Komunikasi Hukum (JKH) 6, No. 2 (2020): 456-464. https://doi.org/10.23887/jkh.v6i2.28096

McMahon, Aisling. "Global Equitable Access to Vaccines, Medicines and Diagnostics for COVID-19: The Role of Patents as Private Governance." Journal of Medical Ethics 47, No. 3 (2021): 142-148. http://dx.doi.org/10.1136/medethics-2020-106795

Muis, Lidya Shery. "Hak Atas Aksesibilitas Obat Paten Bagi Masyarakat." Widya Pranata Hukum: Jurnal Kajian dan Penelitian Hukum 1, No. 1 (2019): 36-64. https://doi.org/10.37631/widyapranata.v1i1.259

Nioi, Matteo, and Pietro Emanuele Napoli. "The waiver of patent protections for COVID-19 vaccines during the ongoing pandemic and the conspiracy theories: lights and shadows of an issue on the ground." Frontiers in Medicine 8 (2021): 756623. https://doi.org/10.3389/fmed.2021.756623

Octarina, Nynda Fatmawati, Evi Kongres, and Mardika Mardika. "Urgensi Penemuan Vaksin Covid-19 sebagai Hak Milik Publik." Pandecta Research Law Journal 16, No. 1 (2021): 106-119. https://doi.org/10.15294/pandecta.v16i1.28997

Oguanobi, Hembadoon Iyortyer. "Broadening the conversation on the TRIPS agreement: access to medicines includes addressing access to medical devices." The Journal of World Intellectual Property 21, No. 1-2 (2018): 70-87. https://doi.org/10.1111/jwip.12091

Poungjinda, Wachiraporn, Shubham Pathak, and Ivan Bimbilovski. "Legal Protection against Patent and Intellectual Property Rights Violations Amidst COVID-19." Emerging Science Journal 7 (2023): 225-237. https://doi.org/10.28991/ESJ-2023-SPER-016

Raharjo, Raden Bagoes Prasetyo, and Kholis Roisah. "Hak Akses Kesehatan Masyarakat Terhadap Hak Paten Produk Farmasi." Jurnal USM Law Review 4, No. 2 (2021): 604-614. http://dx.doi.org/10.26623/julr.v4i2.3231

Samariadi, Samariadi. "Pelaksanaan Compulsory Licensing Paten Obat-obatan Bidang Farmasi di Indonesia Dikaitkan dengan Doha Declaration on the Trips Agreement and Public Health." DE LEGA LATA: Jurnal Ilmu Hukum 1, No. 2 (2016): 448-465. https://doi.org/10.30596/dll.v1i2.804

Sari, Mayas Mutias, Tatty Aryani Ramli “Pelaksanaan Paten oleh Pemerintah Terhadap Obat Antiviral dan Antiretroviral Ditinjau dari UU No. 14 Tahun 2001 Tentang Paten dan Deklarasi Doha.” Prosiding Ilmu Hukum Seminar Penelitian Sivitas Akademika Unisba 1, No. 1 (2015): 9-19. http://dx.doi.org/10.29313/.v0i0.412

Sitorus, Winner. "Kepentingan Umum dalam Perlindungan Paten." Yuridika 29, No. 1 (2014): 39-60. https://doi.org/10.20473/ydk.v29i1.357

Soekanto, Soerjono and Sri Mamudji, Penelitian Hukum Normatif Suatu Tinjauan Singkat (Jakarta: PT Raja Grafindo Persada, 2010).

Sulistianingsih, Dewi, and Raden Muhammad Arvy Ilyasa. "The Impact of Trips Agreement on the Development of Intellectual Property Laws in Indonesia." Indonesia Private Law Review 3, No. 2 (2022): 85-98. https://doi.org/10.25041/iplr.v3i2.2579

Sultana, Janet. et al. "Challenges for drug repurposing in the COVID-19 pandemic era." Frontiers in Pharmacology 11 (2020): 588654. https://doi.org/10.3389/fphar.2020.588654

Suparno, Suparno, and Faisal Santiago. "Perubahan Paradigma Politik Hukum Hak Kekayaan Intelektual (HKI) untuk Mewujudkan Daya Saing Nasional: Studi Perlindungan Rahasia Dagang Bidang Obat-Obatan Tradisional." Lex Publica 5, No. 1 (2018): 8-15.

Telaumbanua, Dalinama. "Tinjauan Yuridis Penetapan Kedaruratan Kesehatan Masyarakat Akibat COVID-19." Jurnal Education and Development 8, No. 2 (2020): 30-30. https://doi.org/10.37081/ed.v8i2.1659

Tharifah, Adzhani, and Agus Sardjono. "Eksistensi Perlindungan Paten atas Vaksin Covid-19." Jurnal Hukum & Pembangunan 51, No. 4 (2022): 1074-1099. https://doi.org/10.21143/jhp.vol51.no4.3302

Utomo, Tomi Suryo. "Deklarasi Doha dalam Perspektif Akses Obat Murah dan Terjangkau: Sebuah Pelengkap Perjanjian TRIPS." Unisia 30, No. 64 (2007): 122-132. https://doi.org/10.20885/unisia.vol30.iss64.art2

Utomo, Tomi Suryo. "Implikasi Pasal-Pasal Pelindung (The Trips Safeguards) dalam UU Paten Indonesia: Kritik, Evaluasi dan Saran Dari Perspektif Akses Terhadap Obat yang Murah dan Terjangkau." Jurnal Hukum IUS QUIA IUSTUM 14, No. 2 (2007): 271-294.

Wesna, Putu Ayu Sriasih. "Doha Declaration sebagai Perlindungan Masyarakat atas Akses Obat Esensial di Negara Berkembang Pasca Trips Agreement." Kertha Wicaksana 14, No. 1 (2020): 56-62. https://doi.org/10.22225/kw.14.1.2020.56-62

WHO. “WHO Director-General’s opening remarks at the media briefing on COVID19 -11 March 2020”, available online at https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020

Wicaksono, Imam. "Politik Hukum Pelindungan Hak Kekayaan Intelektual di Indonesia Pasca di Ratifikasinya TRIPs Agreement." Pena Justisia: Media Komunikasi dan Kajian Hukum 18, No. 1 (2020): 37-47. http://dx.doi.org/10.31941/pj.v18i1.1088